… of management of leptomeningeal metastasis, … with leptomeningeal metastasis from NSCLC.
Future research is needed to further understand the biology of leptomeningeal metastasis …

… options for managing leptomeningeal disease. Systemic … for lung cancer patients with
leptomeningeal disease and a … managing this complication in lung cancer patients. Based …

… We examined the prognosis of patients with leptomeningeal metastasis (LM) from non-small
cell lung cancer (NSCLC) and that stratified by epidermal growth factor receptor (EGFR) …

… The incidence of leptomeningeal carcinomatosis (LC) has increased in patients with
metastatic non–small-cell lung cancer (NSCLC) because of recent improvements in survival. The …

… Leptomeningeal metastasis (LM) is a rare complication of non-small cell lung cancer (NSCLC)
with highly mortality. LM will occur once tumor cells spread to the cerebrospinal fluid (CSF…

… lung cancer patients with leptomeningeal metastases (14). In this model, positive EGFR/ALK,
Karnofsky performance score (KPS) of 60 and more, and the lack of extracranial metastasis …

… in survival from non-small cell lung cancer (NSCLC). Patients … ) can achieve prolonged
disease control and survival with … in the prevalence of leptomeningeal metastasis (LM) from …

… leptomeningeal metastasis (LM), malignant lung cancer cells reach the sanctuary site of
the leptomeningeal … route and thrive in the leptomeninges because of restricted access of …

… microenvironments, the brain parenchyma and the leptomeninges, which differ in cell
types, … who develop brain parenchymal metastases (PM) and leptomeningeal metastasis (LM). …

… , as well as the leading cause of cancer-related death globally.1 Leptomeningeal metastases
(LM) occur in almost 5% of non-small cell lung cancer (NSCLC) patients.2 The median …